Patents by Inventor Haruna Seo

Haruna Seo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20220162604
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: June 30, 2021
    Publication date: May 26, 2022
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20210222169
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Application
    Filed: August 21, 2020
    Publication date: July 22, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acids
    Patent number: 11053497
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 6, 2021
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Antisense nucleic acids
    Patent number: 10781448
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 22, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20200149040
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: June 11, 2019
    Publication date: May 14, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180179538
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: February 22, 2018
    Publication date: June 28, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Antisense nucleic acids
    Patent number: 9988629
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: June 5, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180142245
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acids
    Patent number: 9890381
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: February 13, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20170067048
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: March 11, 2015
    Publication date: March 9, 2017
    Inventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20170067052
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Application
    Filed: October 31, 2016
    Publication date: March 9, 2017
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acids
    Patent number: 9512424
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: December 6, 2016
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20140343266
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Application
    Filed: December 27, 2012
    Publication date: November 20, 2014
    Applicants: NIPPON SHINYAKU CO., LTD., National Center of Neurology and Psychiatry
    Inventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata